SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as the community anticipates upcoming earnings, with some analysts predicting the stock could double its market cap. Bullish sentiment abounds, with some traders drawing comparisons to other high-growth tech stocks. However, concerns about high valuation and potential for a post-earnings pullback remain discussion points.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to a recently announced $9.7 billion AI cloud services agreement with Microsoft, sparking significant community discussion around the implications of the deal. Community members are debating the deal's value, potential impact on earnings, and comparing it to similar deals within the data center sector, while also speculating on potential short squeezes and future price targets.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana (SOL) is trending as the community discusses its potential to recapture higher price levels, with some eyeing key demand zones for potential bounces. Technical analysis is being shared, with traders watching for breakouts or breakdowns from current levels. Bullish sentiment remains for the long term, with some highlighting Solana's fundamentals and real-world asset tokenization potential.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as the community debates whether the recent drop is a buying opportunity or a sign of deeper issues, with some pointing to tariff concerns and overall consumer weakness. Many traders are watching key support levels and potential gap fills, while others express frustration with the stock's performance despite positive earnings and brand recognition. The stock's next move may depend on broader market sentiment and upcoming trade talks.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors debate the company's future amidst concerns about cash flow and potential dilution, despite recent news of partnerships. Community discussions revolve around the stock's persistent downtrend, comparing it unfavorably to competitors like Tesla and Rivian. Some traders express hope for a short squeeze or meme-driven pump, while others remain bearish, citing the need for more affordable models and improved financial performance.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is trending as discussions revolve around its leading position in the weight loss drug market, particularly its competition with Novo Nordisk. Community members are weighing in on the potential impacts of government negotiations on drug pricing, while also eyeing the company's pipeline and potential growth catalysts. Bullish sentiment is fueled by strong sales and raised price targets.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending due to analyst upgrades and positive Phase 1 clinical data for their leukemia drug TERN-701, which is being seen as a potential disruptor in CML treatment, possibly challenging Novartis' Scemblix. The community is discussing the potential for continued momentum and a possible short squeeze, while also debating the company's financial runway and potential for future offerings. Some are drawing comparisons to Altimmune (ALT) and discussing market capitalization.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards as the community debates the implications of increased AI spending and a recent tax hit. While some investors see a buying opportunity due to the company's strong fundamentals and growth potential, others express concern about unclear returns on AI investments. Community chatter includes speculation about potential partnerships and the possibility of a stock split.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending as traders discuss its potential for a ZEC-like surge, possibly fueled by increased attention on privacy coins and its limited supply. Community members are pointing to Dash's fundamentals, such as its lower supply compared to ZEC, and speculating about future price movements, with some eyeing the $100 mark. The conversation also includes mentions of the upcoming Evolution Mainnet release and its potential to introduce DeFi smart contracts to the Dash ecosystem.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant stock drop following the FDA's revised stance on clinical trial data for its Huntington's disease therapy, leading to uncertainty about future approvals. The community is debating the validity of the FDA's concerns, potential for a lawsuit, and if the stock is now a buying opportunity. Discussions also include potential political interference and comparisons to other biotech firms facing regulatory hurdles.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

<ul class="summary-bullets"><li>Verastem reported early trial data showing its experimental oral therapy targeting KRAS-driven cancers was well-tolerated, with no severe gastrointestinal side effects.</li><li>Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.</li><li>Retail traders on Stocktwits responded enthusiastically, calling the update an example of improved, patient-focused design and praising the drug’s tumor-reducing effects.</li></ul>Verastem Oncology shares drew heavy retail chatter on Thursday after the company reported encouraging early results from its Phase 1/2a trial of VS-7375, an investigational oral KRAS G12D inhibitor targeting hard-to-treat solid tumors such as pancreatic and colorectal cancers.<h2 class="st-heading-2">Early Safety Data And Tumor Response</h2>The company said the first two monotherapy dose levels of 400 mg and 600 mg once daily&nbsp;were cleared with no dose-limiting toxicities, and no nausea, vomiting, or diarrhea above Grade 1 was observed. Of the five patients evaluable for efficacy, four experienced tumor reduction and remain on treatment.“Preliminary safety and tolerability data suggest VS-7375 can be administered at efficacious doses while effectively managing gastrointestinal side effects,” said CEO Dan Paterson, adding that the company is seeing “anti-tumor activity among pre-treated patients with advanced pancreatic cancer and other solid tumors.”<h2 class="st-heading-2">Combination Study Now Enrolling</h2>With monotherapy dose escalation continuing to 900 mg, Verastem said it has begun enrolling patients in a combination cohort testing VS-7375&nbsp;with cetuximab in KRAS G12D-mutant solid tumors, including colorectal cancer.Verastem’s Chief Medical Officer John Hayslip said the company is encouraged by the drug’s tolerability and early signs of anti-tumor activity, adding that the ongoing combination trial with cetuximab addresses “a significant unmet need for treatments specifically targeting KRAS G12D-mutant cancers.”The company plans to report an interim safety and efficacy update in the first half of 2026 and expand the trial globally following dose optimization.<h2 class="st-heading-2">Background On The Candidate</h2>VS-7375 is the lead program from Verastem’s collaboration with GenFleet Therapeutics, which is running a parallel study in China under the name GFH375. GenFleet previously selected 600 mg once daily as the recommended Phase 2 dose, citing similar safety and response patterns.The KRAS G12D mutation accounts for 26% of all KRAS mutations and is most prevalent in pancreatic, colorectal, endometrial, and lung cancers, which&nbsp;have few or no targeted treatment options.<h2 class="st-heading-2">Stocktwits Bulls Cheer Early Trial Results</h2>On Stocktwits, retail sentiment for Verastem was ‘extremely bullish’ amid a 123% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:967/134;" src="https://news.stocktwits-cdn.com/vstm_ss_jpg_a440d5807e.webp" alt="vstm ss.jpg" width="967" height="134"><figcaption>VSTM sentiment and message volume as of October 23 | Source: Stocktwits</figcaption></figure>One user said they were encouraged by Verastem’s latest update, calling it an example of how small refinements in trial design and dosing can meaningfully improve patient experience and tolerability.<stembedurl>https://stocktwits.com/CrozrX/message/633534378</stembedurl>Another user expressed optimism about Verastem, noting that the drug appeared to reduce tumor size while causing limited side effects.<stembedurl>https://stocktwits.com/UWilDue0/message/633520498</stembedurl><a href="https://stocktwits.com/symbol/VSTM">Verastem’s stock</a> has risen 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects

Four of five evaluable patients showed tumor reduction, prompting optimism around the drug’s potential for pancreatic and colorectal cancer treatment.

Equity

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced encouraging preliminary data from...

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Verastem (VSTM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...

Best Momentum Stocks to Buy for Oct. 21

VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.

New Strong Buy Stocks for Oct. 21: NEM, AS and More

NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

The mean of analysts' price targets for Verastem (VSTM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$9.93
Prev Close	$9.45
Open	$9.36
Dividend Yield	0.00%
50-Day Moving Average	$9.09
Beta	1.47
Avg. Volume	2.16M
PE Ratio	-2.69

52-Week High	$11.25
52-Week Low	$3.46
Market Capitalization	$581.6M
EPS (Annual)	-$3.66
Price to Book	16.12
Revenue Per Employee	$128,205.13
Enterprise Value/EBITDA	N/A

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc